Recent News

• 02.05.2026 - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
• 02.02.2026 - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
• 01.29.2026 - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
• 01.06.2026 - Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
• 12.30.2025 - The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
• 12.10.2025 - Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Recent Filings

• 02.05.2026 - 144 Report of proposed sale of securities
• 02.04.2026 - 144 Report of proposed sale of securities
• 02.03.2026 - 144 Report of proposed sale of securities
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 144 Report of proposed sale of securities
• 01.06.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 144 Report of proposed sale of securities
• 01.06.2026 - 144 Report of proposed sale of securities
• 01.06.2026 - 8-K Current report